DEF 14A: Avantor, Inc. Outlines Director Nominees, Governance Practices, and Executive Compensation in Proxy Statement

Avantor's proxy statement details the company's director nominees, corporate governance practices, and executive compensation for the upcoming 2024 Annual Meeting of Stockholders.

Summary

• Avantor, Inc. has released its proxy statement for the 2024 Annual Meeting of Stockholders, scheduled for May 9, 2024.
• The document outlines the agenda, which includes the election of nine directors, approval of amendments to the certificate of incorporation, ratification of the appointment of Deloitte & Touche LLP as the independent registered public accounting firm, and advisory approval of named executive officer compensation.
• The Board of Directors recommends voting for all director nominees, the proposed amendments to the certificate of incorporation, the ratification of Deloitte & Touche LLP, and the advisory approval of executive compensation.
• The proxy statement highlights Avantor's commitment to good corporate governance, including a diverse and experienced Board of Directors, regular stockholder engagement, and policies prohibiting short sales, hedging, and pledging of stock by directors and officers.
• Executive compensation is designed to support the longevity and stability of the company by driving long-term business outcomes and promoting strong governance practices.
• The company's compensation program includes a significant percentage of variable compensation tied to performance, market comparison against a relevant peer group, and robust stock ownership guidelines.
• The proxy statement also details Avantor's sustainability initiatives, including setting new science-based climate targets and expanding its Responsible Supplier program globally.
• The company's Board of Directors currently has ten members, but Christi Shaw will not stand for reelection.
• The Board has determined that each of Juan Andres, John Carethers, Lan Kang, Joseph Massaro, Mala Murthy, Jonathan Peacock, Michael Severino, Christi Shaw and Gregory Summe is independent.
• The company's new operating model will sharpen its focus in further building its Bioscience Production and Lab Solutions businesses, increase efficiency and position Avantor for long-term growth.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative information. While there are positive aspects such as sustainability initiatives and strategic investments, the failure to meet financial metrics and the departure of key executives temper the overall sentiment.

Positives

• Avantor is strategically integrated into its customers' laboratory and manufacturing workflows around the world through research, development, and commercialization.
• The company is specified into 85 percent of the top 20 biologic therapies.
• Avantor has made purposeful, strategic investments in manufacturing capacity, supply chain, innovation and digital capabilities to drive efficiencies and position the company for future growth.
• The company is doubling the size of its Bridgewater, N.J. innovation center.
• Sustainability remains core to Avantor's long-term growth strategy and the value it delivers.
• The company has set new science-based climate targets and is expanding its Responsible Supplier program globally.
• Avantor is well positioned to continue strengthening its partnership with global customers operating in attractive innovation-driven growth markets.
• The company's experienced management team and Board of Directors will continue to focus on strong execution in pursuit of stockholder value creation.
• The company achieved the Human Rights Campaign Corporate Equality Index score of 100.
• The company has established the Leader Success Model and assessment to develop and measure leader competency in future ready capabilities.

Risks

• The proxy statement references 'Risk Factors' in Avantor's most recent Annual Report on Form 10-K, indicating potential business risks that investors should consider.
• The company's ability to achieve its targeted gross annual run rate savings of ~$300 million in 36 months through its cost optimization initiative is subject to execution risk.
• The company's ability to meet its new 2030 near-term climate targets is subject to various factors, including technological advancements and regulatory changes.

Future Outlook

Avantor is well positioned to continue strengthening its partnership with global customers operating in attractive innovation-driven growth markets, with a focus on strong execution in pursuit of stockholder value creation.

Management Comments

• Avantor earned new and expanded multi-year customer relationships that reflect our value as a trusted partner from discovery to delivery.
• We are strategically integrated into our customers laboratory and manufacturing workflows around the world through research, development, and commercialization.
• We have also made purposeful, strategic investments in manufacturing capacity, supply chain, innovation and digital capabilities to drive efficiencies and position the company for future growth.
• At our Investor Day in December 2023, we introduced Avantors new operating model, which will sharpen our focus in further building our Bioscience Production and Lab Solutions businesses, increase efficiency and position Avantor for long-term growth.
• In addition to the growth opportunities that we expect our new model to unlock, we initiated a multi-year cost-out initiative to streamline our operations, footprint, and broader cost base.
• Sustainability remains core to our long-term growth strategy and the value we deliver.

Industry Context

Avantor operates in the life sciences and advanced technology industries, providing mission-critical products, services, and technologies. The company's performance is influenced by trends in these industries, including advancements in modern medicine and technology, and the demand for biologic therapies.

Comparison to Industry Standards

• The document mentions a peer group of companies used for benchmarking executive compensation, including Agilent Technologies, Baxter International, and Illumina.
• The company's Total Recordable Incident Rate (TRIR) of 0.43 places it in the top quartile for safety performance in its relevant industries.
• The company is compared to the S&P 500 Health Care Index for TSR performance.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders are encouraged to vote on key proposals that will shape the company's governance and executive compensation.
• Employees may be affected by the company's cost optimization initiative and changes in leadership.
• Customers can expect continued innovation and strategic integration into their workflows.
• Suppliers are subject to the Avantor Responsible Supplier Program, which aims to increase transparency and improve responsible business practices.

Next Steps

• Stockholders are encouraged to vote by proxy in advance of the Annual Meeting.
• The Board will initiate a search process to identify qualified candidates to replace Ms. Shaw in line with the nomination process outlined in our Corporate Governance Guidelines.

Key Dates

Keywords

executive compensation, corporate governance, director nominees, annual meeting, sustainability, proxy statement, Avantor